RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Yasmine Kanaan and Robert L. Copeland.
Connection Strength

5.960
  1. Kanaan Y, Copeland RL. The link between vitamin D and prostate cancer. Nat Rev Cancer. 2022 08; 22(8):435.
    View in: PubMed
    Score: 0.896
  2. Copeland RL, Kanaan Y. New targets in triple-negative breast cancer. Nat Rev Cancer. 2021 12; 21(12):744.
    View in: PubMed
    Score: 0.855
  3. Copeland RL, Beyene D, Apprey V, Daremipouran MR, Naab TJ, Kassim OO, Kanaan YM. DHPLC Elution Patterns of VDR PCR Products Can Predict Prostate Cancer Susceptibility in African American Men. Cancer Genomics Proteomics. 2017 Nov-Dec; 14(6):461-467.
    View in: PubMed
    Score: 0.644
  4. Kanaan YM, White DF, Das JR, Berhe S, Bakare O, Kenguele H, Beyene D, Zhou Y, Day AA, Copeland RL. Cytotoxic effects of N-(3-chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on androgen-dependent and -independent prostate cancer cell lines. Anticancer Res. 2010 Feb; 30(2):519-27.
    View in: PubMed
    Score: 0.377
  5. Kanaan YM, Das JR, Bakare O, Enwerem NM, Berhe S, Beyene D, Williams V, Zhou Y, Copeland RL. Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent. Anticancer Res. 2009 Jan; 29(1):191-9.
    View in: PubMed
    Score: 0.349
  6. Copeland RL, Das JR, Bakare O, Enwerem NM, Berhe S, Hillaire K, White D, Beyene D, Kassim OO, Kanaan YM. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines. Anticancer Res. 2007 May-Jun; 27(3B):1537-46.
    View in: PubMed
    Score: 0.311
  7. Beyene D, Naab T, Apprey V, Ricks-Santi L, Esnakula A, Qasim M, George M, Minoza KG, Copeland RL, Broome C, Kanaan Y. Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer. J Cancer Biol. 2023; 4(1):3-16.
    View in: PubMed
    Score: 0.230
  8. Qasim M, Ricks-Santi LJ, Naab TJ, Rajack F, Beyene D, Abbas M, Kassim OO, Copeland RL, Kanaan Y. Inverse Correlation of KISS1 and KISS1R Expression in Triple-negative Breast Carcinomas from African American Women. Cancer Genomics Proteomics. 2022 Nov-Dec; 19(6):673-682.
    View in: PubMed
    Score: 0.228
  9. Turkistani S, Sugita BM, Fadda P, Marchi R, Afsari A, Naab T, Apprey V, Copeland RL, Campbell MC, Cavalli LR, Kanaan Y. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer. BMC Cancer. 2021 Jul 27; 21(1):861.
    View in: PubMed
    Score: 0.209
  10. Robinson AGJ, Kanaan YM, Copeland RL. Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines. Anticancer Res. 2020 Dec; 40(12):6623-6635.
    View in: PubMed
    Score: 0.200
  11. Beyene DA, Daremipouran MR, Apprey V, Naab T, Kassim OO, Copeland RL, Kanaan YM. The Association Between the Genetic VDR SNP c.907+75C>T and Prostate Cancer Risk Is Modified by Tanning Potential. Cancer Genomics Proteomics. 2020 Nov-Dec; 17(6):739-745.
    View in: PubMed
    Score: 0.198
  12. Daremipouran MR, Beyene D, Apprey V, Naab TJ, Kassim OO, Copeland RL, Kanaan YM. The Association of a Novel Identified VDR SNP With Prostate Cancer in African American Men. Cancer Genomics Proteomics. 2019 Jul-Aug; 16(4):245-255.
    View in: PubMed
    Score: 0.181
  13. Owrang M, Copeland RL, Ricks-Santi LJ, Gaskins M, Beyene D, Dewitty RL, Kanaan YM. Breast Cancer Prognosis for Young Patients. In Vivo. 2017 Jul-Aug; 31(4):661-668.
    View in: PubMed
    Score: 0.157
  14. Bamji ZD, Washington KN, Akinboye E, Bakare O, Kanaan YM, Copeland RL. Apoptotic Effects of Novel Dithiocarbamate Analogs of Emetine in Prostate Cancer Cell Lines. Anticancer Res. 2015 Sep; 35(9):4723-32.
    View in: PubMed
    Score: 0.139
  15. Winchester D, Ricks-Santi L, Mason T, Abbas M, Copeland RL, Beyene D, Jingwi EY, Dunston GM, Kanaan YM. SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients. Anticancer Res. 2015 Jul; 35(7):3811-9.
    View in: PubMed
    Score: 0.137
  16. Kassim OO, Copeland RL, Kenguele HM, Nekhai S, Ako-Nai KA, Kanaan YM. Antiproliferative activities of Fagara xanthoxyloides and Pseudocedrela kotschyi against prostate cancer cell lines. Anticancer Res. 2015 Mar; 35(3):1453-8.
    View in: PubMed
    Score: 0.134
  17. Jingwi EY, Abbas M, Ricks-Santi L, Winchester D, Beyene D, Day A, Naab TJ, Kassim OO, Dunston GM, Copeland RL, Kanaan YM. Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men. Anticancer Res. 2015 Mar; 35(3):1549-58.
    View in: PubMed
    Score: 0.134
  18. Beyene D, Daremipouran M, Apprey V, Williams R, Ricks-Santi L, Kassim OO, Naab TJ, Kanaan YM, Copeland RL. Use of tanning potential as a predictor for prostate cancer risk in African-American men. In Vivo. 2014 Nov-Dec; 28(6):1181-7.
    View in: PubMed
    Score: 0.131
  19. Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, Copeland RL, Gabrielson E, Dewitty RL. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics Proteomics. 2014 Nov-Dec; 11(6):279-94.
    View in: PubMed
    Score: 0.131
  20. Copeland RL, Das JR, Kanaan YM, Taylor RE, Tizabi Y. Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity. Neurotox Res. 2007 Jul; 12(1):61-9.
    View in: PubMed
    Score: 0.079
  21. Copeland RL, Leggett YA, Kanaan YM, Taylor RE, Tizabi Y. Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: implications for Parkinson's disease. Neurotox Res. 2005 Nov; 8(3-4):289-93.
    View in: PubMed
    Score: 0.070
  22. Almohaywi M, Sugita BM, Centa A, Fonseca AS, Antunes VC, Fadda P, Mannion CM, Abijo T, Goldberg SL, Campbell MC, Copeland RL, Kanaan Y, Cavalli LR. Deregulated miRNA Expression in Triple-Negative Breast Cancer of Ancestral Genomic-Characterized Latina Patients. Int J Mol Sci. 2023 Aug 22; 24(17).
    View in: PubMed
    Score: 0.060
  23. Moses-Fynn E, Tang W, Beyene D, Apprey V, Copeland R, Kanaan Y, Kwabi-Addo B. Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men. PLoS One. 2018; 13(9):e0203322.
    View in: PubMed
    Score: 0.043
  24. Ren X, Ghassemi P, Kanaan YM, Naab T, Copeland RL, Dewitty RL, Kim I, Strobl JS, Agah M. Kernel-Based Microfluidic Constriction Assay for Tumor Sample Identification. ACS Sens. 2018 08 24; 3(8):1510-1521.
    View in: PubMed
    Score: 0.042
  25. Brandy Y, Ononiwu I, Adedeji D, Williams V, Mouamba C, Kanaan Y, Copeland RL, Wright DA, Butcher RJ, Denmeade SR, Bakare O. Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines. Invest New Drugs. 2012 Aug; 30(4):1709-14.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support